Literature DB >> 8472450

Avascular necrosis of the femoral head in sickle cell disease. An integrated classification.

M Sadat-Ali1.   

Abstract

Avascular necrosis of the femoral head (ANFH) is one of the crippling complications of sickle cell disease (SCD), and to date there is no classification that could identify patients in the early phase of the necrosis. Based on the experience of 66 ANFH in 43 patients with SC hemoglobinopathy, the necrosed hips were classified into four grades, Grade I to Grave IV, based on patient history, clinical evaluation, and radiologic examination. In Grade I, the patient complains of the mildest symptoms with minimal clinical signs and radiologic changes. The most severe form, Grade IV, is where the findings are unbearable pain with disability and marked roentgenographic evidence of osteonecrosis. This classification identifies patients in Grade I and II, which, with early diagnosis and proper management, could delay further deterioration of the necrosed femoral head.

Entities:  

Mesh:

Year:  1993        PMID: 8472450

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  5 in total

1.  The spine in sickle cell disease.

Authors:  M Sadat-Ali; A Ammar; J R Corea; A W Ibrahim
Journal:  Int Orthop       Date:  1994-06       Impact factor: 3.075

Review 2.  A review of the literature on the multiple dimensions of chronic pain in adults with sickle cell disease.

Authors:  Lou Ella V Taylor; Nancy A Stotts; Janice Humphreys; Marsha J Treadwell; Christine Miaskowski
Journal:  J Pain Symptom Manage       Date:  2010-07-24       Impact factor: 3.612

Review 3.  Sickle Cell Disease: A Review of Nonpharmacological Approaches for Pain.

Authors:  Hants Williams; Paula Tanabe
Journal:  J Pain Symptom Manage       Date:  2015-11-17       Impact factor: 3.612

4.  Stem Cell Therapy for Avascular Necrosis of Femoral Head in Sickle Cell Disease: Report of 11 Cases and Review of Literature.

Authors:  Mir Sadat-Ali; Md Q Azam; Ezzat M Elshabouri; Ahmad M Tantawy; Sadananda Acharya
Journal:  Int J Stem Cells       Date:  2017-11-30       Impact factor: 2.500

5.  Revision hip arthroplasty in sickle cell disease.

Authors:  Aydýner Kalacý; Cenk Ozkan; Emre Toğrul
Journal:  Ann Saudi Med       Date:  2007 Mar-Apr       Impact factor: 1.526

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.